Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24998260 | 0.78 | ALDH1A1 (0.30) | ALDH1A1L3MBTL1 | |
| SCHEMBL24997426 | 0.74 | CYP1A2 (0.30) | — | |
| SCHEMBL1047966 | 0.74 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL18370534 | 0.74 | HPGD (0.30) | HPGDHTT | |
| SCHEMBL24998124 | 0.70 | ALDH1A1 (0.35) | KMT2ALMNAALDH1A1POLBL3MBTL1 | |
| SCHEMBL23535034 | 0.70 | KMT2A (0.42) | KMT2ALMNAALDH1A1L3MBTL1HPGD | |
| SCHEMBL31174787 | 0.70 | ALDH1A1 (0.38) | ALDH1A1POLBL3MBTL1 | |
| SCHEMBL17093153 | 0.67 | ALDH1A1 (0.36) | ALDH1A1MAPTHPGD | |
| SCHEMBL17093148 | 0.67 | IMPDH2 (0.32) | — | |
| SCHEMBL17093180 | 0.67 | SCN9A (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230037538-A1 | ANTI-ALS COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-09 | — | — | US | disclosed |
| EP-4076460-A1 | PRMT5 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2022-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230037538-A1 | ANTI-ALS COMPOUNDS | TARDBP, GRN, NLN | KMT2A 4019/4885LMNA 390/4885ALDH1A1 3882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.